Autopsy report · NCT02958202
Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)
Cause of deathRegulatory or ethics, also funding or business
“Regulatory approval was not obtained for drisapersen, hence BioMarin is stopping the development of all exon skipping oligonucleotides in DMD.”
Life of this trial
- Registered 6 months after it had already started.
- Ran for about 5 months before it stopped.
- 7 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- BioMarin Pharmaceutical
- Sponsor type
- Industry
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- BMN 044 IV 6 mg/kg; BMN 044 IV 9 mg/kg; BMN 044 SC 6 mg/kg
- Participants
- 7
- Sites
- 5
- Countries
- Belgium, Italy, Netherlands, Sweden
Trials that died the same way
- A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
“The study was withdrawn because BioMarin decided to end the overall development program. The study withdrawal was not due to any patient safety concerns.” - Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
“US FDA is streamlining the Biosimilar development. Thus, Biocon decided to terminate the study.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.